EyePoint, Inc.
Customers
1
1 active
Suppliers
0
None disclosed
Largest customer
54.8%
ANIP · FY to 2025-12-31
Named-customer revenue
$17.2M
1 customer · FY to 2025-12-31
Latest period
Dec 31, 2025
10-K filed 2026-03-05
Customers 1
Companies EYPT discloses as major customers, as a share of EYPT revenue. 1 active, 0 lapsed.
| Company | % of EYPT revenue | Est. revenue | Period | Trend | Status | Source |
|---|---|---|---|---|---|---|
| ANIP ANI PHARMACEUTICALS INC |
54.8% | $17.2M | FY 2025-12-31 | −38.8pp | Active | 10-K 2026-03-05 |
For the year ended December 31, 2025 revenues from ANI Pharmaceuticals, Inc. (ANI), formerly Alimera Sciences, Inc. and SWK Funding LLC (SWK), accounted for 54.8% and 40.4% of total revenues, respectively.As of December 31, 2024, accounts receivable from ANI accounted for 72.3% and accounts receivable from OncoSil Medical Ltd. accounted for 16.5% of total accounts receivable, respectively. | ||||||
Alerts are coming
Get an email when EYPT's disclosed suppliers or customers change. Join the list and we'll tell you when alerts launch. One email, no spam.